Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma
出版年份 2022 全文链接
标题
Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma
作者
关键词
Salivary Gland Neoplasms [Mesh], Salivary duct carcinoma, Genes, erbB-2 [Mesh], HER2, Trastuzumab [Mesh], Pertuzumab, Ado-Trastuzumab Emtansine [Mesh]
出版物
ORAL ONCOLOGY
Volume 125, Issue -, Pages 105703
出版商
Elsevier BV
发表日期
2022-01-05
DOI
10.1016/j.oraloncology.2021.105703
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies
- (2021) Anja van de Stolpe et al. Frontiers in Genetics
- Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
- (2021) Jose Perez et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
- (2021) F. Schettini et al. ESMO Open
- LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
- (2021) J. Cortés et al. ANNALS OF ONCOLOGY
- Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade
- (2021) Gerben Lassche et al. Cancers
- The Benefits of Adjuvant Trastuzumab for HER‐2‐Positive Salivary Gland Cancers
- (2020) Glenn J. Hanna et al. ONCOLOGIST
- 1423MO End-of-study analysis from JACOB: A phase III study of pertuzumab (P) + trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC)
- (2020) J. Tabernero et al. ANNALS OF ONCOLOGY
- Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review
- (2020) M.J.M. Uijen et al. CANCER TREATMENT REVIEWS
- Quantitative Measurement of Functional Activity of the PI3K Signaling Pathway in Cancer
- (2019) Anja van de Stolpe Cancers
- Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types
- (2019) Anja van de Stolpe et al. Scientific Reports
- Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial.
- (2019) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients
- (2019) Wim Boxtel et al. INTERNATIONAL JOURNAL OF CANCER
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands
- (2018) Eline Boon et al. INTERNATIONAL JOURNAL OF CANCER
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas
- (2018) Jong Chul Park et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma
- (2018) Hideaki Takahashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands
- (2017) Eline Boon et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma
- (2017) Wim van Boxtel et al. ORAL ONCOLOGY
- Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy
- (2017) Nicole C. Schmitt et al. ORAL ONCOLOGY
- Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification
- (2017) Soichiro Takase et al. Oncotarget
- Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses
- (2016) Kenji Nakano et al. ACTA OTO-LARYNGOLOGICA
- Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer
- (2016) M. G. Dalin et al. CLINICAL CANCER RESEARCH
- Management of Salivary Gland Tumours: United Kingdom National Multidisciplinary Guidelines
- (2016) S Sood et al. JOURNAL OF LARYNGOLOGY AND OTOLOGY
- Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers
- (2015) Laura D. Locati et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- Prognostic factors and oncologic outcomes of 56 salivary duct carcinoma patients in a single institution: High rate of systemic failure warrants targeted therapy
- (2014) Jong-Lyel Roh et al. ORAL ONCOLOGY
- Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database
- (2013) Vijayvel Jayaprakash et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
- (2012) Thuy Vu et al. Frontiers in Oncology
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started